Novo Nordisk (NOVOB DC) reports triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China; The primary endpoint of the trial was the percentage change in body weight from baseline after 24 weeks of treatment

Novo Nordisk's positive results from the phase 2 trial of UBT251, showing significant weight loss, could signal strong future performance for the company if this trend continues into global trials.

Newsquawk StaffPublished 24 Feb 2026, 09:00 UTCOn the live feed at 08:40 UTC — 3 more headlines followed before this page went public

Newsquawk headlinesUTC

08:45

Newsquawk Bond Auction Previews - 24th February 2026

08:42

Britain imposes new sanction on Russia's Transneft oil operation

08:40

Novo Nordisk (NOVOB DC) reports triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China; The primary endpoint of the trial was the percentage change in body weight from baseline after 24 weeks of treatment

08:20

EUROPEAN OPEN: STAN LN profit miss, announces USD 1.5bln buyback; FME GY profits surge; TEF SM core profit accelerates; SAP GY settles with TDC; NOVOB DC downgraded

08:17

China's Commerce Ministry calls on US to abandon unilateral tariff; will adjust countermeasures and monitor US actions

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “We look forward to reporting data from a global trial with UBT251 conducted by Novo Nordisk next year.”

Context

The confirmation of safety and tolerability alongside these results adds to the therapy's attractiveness, which may bolster investor confidence and influence stock performance as the market anticipates further developments.

All markets · last 90 days

Recent headlines that moved markets

METALS/1 Sep · 08:06

Two oil supertankers were reportedly hit by projectiles in the Strait of Hormuz, reports citing Marisks suggest (details light)

Spot Gold, after we published−1.0%

Further upside seen in energy, downside in equities and fixed and fresh USD strength following this. - Spot gold slipped to USD 4390/oz before dipping lower.

FX/28 Aug · 14:00

Fed Chair Warsh says Fed has more work to do unless confident underlying inflation is moving towards 2% objective

+0.5%DXY

ENERGY/27 Aug · 17:46

The Trump administration has repeatedly told mediators it has no interest in going back to the terms of the MoU it reached with Iran in June, reports WSJ citing sources

+1.4%Brent crude

EQUITIES/26 Aug · 12:56

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

+2.6%market

ENERGY/25 Aug · 19:26

A ceasefire between the US and Iran has been agreed upon, it includes free navigation in the Strait of Hormuz and will be announced in the coming days, reports Ria citing Pakistani and Iranian sources

−2.4%Brent crude

FX/2 Sep · 13:45

BoC holds rates as expected as 2.25%

−0.3%USD/CAD

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.